Other top stories

Similar Outcomes With 2-Week and 4-Week Tapers to Xanomeline-Trospium

September 10, 2026

Xanomeline-Trospium and EPS: Low Rates Across Trials, Comparative Data Remain Limited

September 10, 2026

Improved but Not Recovered: The Relapsing Course of Generalized Anxiety Disorder

August 28, 2026

Safety Across Classic Psychedelics in GAD: What Three Investigational Programs Show So Far

August 28, 2026

The Weakened Brake: Circuit and Synaptic Biology in Generalized Anxiety Disorder

August 1, 2026

The Receptor at the Center of Psychedelic Therapies for GAD

August 1, 2026

Other stories

2026 Congress Coverage: The Persistence Problem in GAD and Treatment-Resistant Depression

July 27, 2026

Psychedelics Are Advancing in GAD, but None Are Yet Approved

July 16, 2026

How Generalized Anxiety Disorder Presents, and Why It Is Often Missed

July 7, 2026

Generalized Anxiety Disorder: A Persistent Burden Despite Standard Treatments

July 7, 2026

Why Your Psychiatric Patients Aren’t Sleeping: CBT-I and a Pathway That Finally Works

March 30, 2026

The Sleep Disorder You Are Missing in Your Psychiatric Patients & The Modern Solution For It

March 11, 2026

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe